MADRID — A new multibiomarker disease test, in combination with clinical measures, may be effective in predicting joint damage in patients with rheumatoid arthritis, according to data presented at the EULAR Annual Congress.
“This meta-analysis of six cohorts was done to demonstrate the relationship between the Vectra DA score [(Crescendo Bioscience] and risk for radiographic progression,” Eric Sasso, MD, vice president of Medical and Scientific Affairs at Crescendo Bioscience, told Healio Rheumatology. “The study included more than 800 patients with [rheumatoid arthritis] RA who received conventional [disease-modifying antirheumatic drugs] DMARDs alone or with adalimumab, infliximab or abatacept.”
The researchers determined frequency of radiographic progression (RP) during the course of 1 year using Vectra DA score categories (low, moderate or high) at the start of the year in four cohorts, and at the end of the year in the remaining two cohorts. They used the threshold for change in total modified Sharp score in each study as the definition for RP. For each study, relative risk (RR) for RP was calculated.
The researchers found the overall rates of RP ranged from 10% to 26%. In each study, patients with high vs. low/moderate Vectra DA scores had a higher prevalence of RP (>44 vs. ≤44). High Vectra DA scores were associated with a 3.6-times to 9.5-times greater likelihood of RP development vs. patients with low VECTRA DA scores.
A meta-analysis of three cohorts — the Leiden, SWEFOT Year 1 and OPERA Year 1 — found high Vectra DA scores were associated with a 5.1-fold greater likelihood of developing RP.
High DAS28-CRP scores were associated with a 1.4-times greater likelihood of developing RP, and high CRP scores were associated with 1.6-times greater likelihood of RP.
“We believe combining the Vectra DA score with conventional clinical measures will enable rheumatologists to individualize treatment plans for their patients,” Sasso said. “For example, a doctor might consider more actively monitoring a patient’s condition, or they may change or alter dosages of medications.” – by Jennifer Bryne
Curtis JR, et al. Poster #THU0091. Presented at: EULAR Annual Congress; June 14-17, 2017; Madrid.
Disclosure: Sasso reports he is a shareholder of Myriad Genetics and an employee of Crescendo Bioscience Inc.